Apitopes P1 and P17 induce proliferation in human PBMCs from healthy blood donors and patients with HA
| . | Response to rhFVIII and 1 or both apitopes . | Response to 1 or both apitopes (FVIII responders) . | No response to rhFVIII . |
|---|---|---|---|
| FVIII+/+ healthy donors | 11/15 (73%) | 9/11 (82%) | 4/15 (27%) |
| FVIII−/− patients | 14/23 (61%) | 9/14 (64%) | 9/23 (39%) |
| . | Response to rhFVIII and 1 or both apitopes . | Response to 1 or both apitopes (FVIII responders) . | No response to rhFVIII . |
|---|---|---|---|
| FVIII+/+ healthy donors | 11/15 (73%) | 9/11 (82%) | 4/15 (27%) |
| FVIII−/− patients | 14/23 (61%) | 9/14 (64%) | 9/23 (39%) |
PBMCs isolated from peripheral blood of healthy donors or patients with HA were cultured with graded concentrations of rhFVIII or peptides P1 and P17. PBMC proliferation was assessed at day 6 to day 8 of culture by [3H]-thymidine incorporation and expressed as the stimulation index (SI). A positive response to peptides P1 or P17 and rhFVIII was defined as SI > 2.